ArticleScientific reports2021

Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy.

Hidetaka Matsumoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.